Neogen partners with Merck on new line of gene-testing products; Peak sees rising demand for hemp-based supplements; Bayer awards $70K in scholarship funds;

> Neogen ($NEOG) announced that Merck ($MRK) Animal Health will market its new line of genomic testing products for dairy producers as part of a strategic agreement between the two companies. Release

> Peak Pharmaceuticals ($PKPH), a maker of hemp-based supplements for pets, announced that its revenues in its fiscal second quarter grew 36% from the previous quarter to $220,932. Release

> Bayer HealthCare Animal Health awarded $70,000 in scholarship money to 28 veterinary students who participated in the company's annual Excellence in Communication competition, which challenged them to submit a filmed interaction with a client showing effective empathy and listening skills. Release

> Virbac named Robert "Mac" MacGregor vice president of industrial operations and site manager for the company's Bridgeton, MO facility. Release

> VetStem Biopharma, which markets regenerative treatments for horses and pets, named veterinarian Ross Rich as director of clinical development. Release

> The Nature Conservancy announced that 150 bats were successfully treated for the deadly fungal disease white-nose syndrome and released back into the wild as part of a field trial of a bacterium-based treatment that inhibits growth of the fungus. Release

> TheraCell, which is developing regenerative tissue-repair treatments for the human and veterinary markets, appointed spine surgeon Gunnar B.J. Andersson of Rush University Medical Center as a director and member of its surgeon advisory board. Release

> Veterinary Pharmacy Reference On-line, a joint venture of BMC Software Development and CaerVision, partnered with Timeless Veterinary Systems to develop a new veterinary pharmacy software product. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…